- Previous Close
4.5500 - Open
4.5520 - Bid --
- Ask --
- Day's Range
4.4940 - 4.5940 - 52 Week Range
3.8160 - 9.3500 - Volume
36,807 - Avg. Volume
77,497 - Market Cap (intraday)
215.692M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0700 - Earnings Date Sep 25, 2024 - Sep 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.80
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
www.nanobiotix.comRecent News: NANO.PA
View MorePerformance Overview: NANO.PA
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NANO.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NANO.PA
View MoreValuation Measures
Market Cap
213.42M
Enterprise Value
188.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.53
Price/Book (mrq)
--
Enterprise Value/Revenue
6.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-109.64%
Return on Assets (ttm)
-19.72%
Return on Equity (ttm)
--
Revenue (ttm)
36.21M
Net Income Avi to Common (ttm)
-39.7M
Diluted EPS (ttm)
-1.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
75.28M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.27M